You are about to learn how to judge a scientific hypothesis among peers.
A therapeutic hypothesis lands in your hands — sourced and structured (mechanism, criticism, falsifiability). You adjust three gauges (Reproducibility / Parsimony / Rigor) based on your intuition, then swipe: right if convincing, left if you want to dig deeper. You can also skip without verdict.
Bactaegion's open-source pharmaceutical pipeline (NS-2) relies on the collective ability to separate solid hypotheses from empty speculation. With the 478,206 new candidate families published by Pasteur (May 2026), hundreds of therapeutic hypotheses will emerge — a distributed judgment layer is needed to prioritize those worth pushing to a non-commercial clinical sponsor (DNDi, GARDP). You train here on 5 calibrated internal Bactaegion hypotheses — so you can judge the real contributive ones (milestone J3 of the public roadmap).
This gesture serves NS-2 — produce open-science pharmacological hits — by training the peers who will judge the contributive hypotheses. Details on /en/mission/#ns2 and /en/roadmap/.